AI Summary Wegovy (semaglutide 2.4 mg) produced average weight loss of 15% or more in clinical trials, per Novo Nordisk's FDA-approved prescribing information.
Medically reviewed.
Wegovy (semaglutide) is a prescription GLP-1 receptor agonist approved for chronic weight management. It is part of the same drug class as Ozempic, but at a higher dose. Because obesity and insulin resistance drive MASLD and MASH, some healthcare providers use Wegovy to address these underlying metabolic risk factors — and since August 2025, the FDA has also approved it specifically for adults with MASH and liver fibrosis.
This page covers Wegovy's role in MASLD and MASH management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Wegovy fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT WEGOVY TREATMENT
Wegovy is a prescription medicine that contains semaglutide, a type of medication known as a GLP-1 receptor agonist. It is part of the same drug family as Ozempic, but at a higher dose (2.4 mg), designed for long-term weight loss and weight maintenance.
Wegovy is approved for chronic weight management in adults and adolescents with obesity, or in adults who are overweight with at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. Because obesity and insulin resistance are closely linked to MASLD and MASH, some healthcare providers use Wegovy to address these underlying metabolic risk factors. In August 2025, the FDA expanded Wegovy's approval to include adults with MASH and liver fibrosis, making it one of the few medications specifically indicated for this liver condition.
It is typically used as part of a broader, personalized treatment plan that may include dietary changes, physical activity, and regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs) or imaging.
WHO WEGOVY MAY BE SUITABLE FOR
Eligibility for Wegovy depends on the medication's approved uses, your diagnosis, and your individual health needs. Wegovy is approved for chronic weight management, so it may be considered for people who meet these criteria and who also have MASLD or MASH linked to metabolic risk factors such as obesity or insulin resistance.
Your medical history, current health status, liver condition, and any other medications you take all factor into whether Wegovy is an appropriate option for you.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Wegovy. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition, metabolic health, and treatment goals. Your doctor will weigh the potential benefits against any risks before determining whether Wegovy fits safely into your broader care plan.
ELIGIBILITY OVERVIEW
Wegovy may be considered for adults with the following conditions, risk factors, or treatment goals:
Before recommending Wegovy, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW WEGOVY CAN HELP YOUR LIVER
Wegovy activates GLP-1 receptors, which act on the brain's appetite centers to reduce hunger and cravings, and slows how quickly food leaves the stomach so you feel full for longer and eat smaller meals. These effects support significant, sustained weight loss when combined with a reduced-calorie diet and increased physical activity.
These actions target the metabolic drivers behind MASLD and MASH: excess body weight and insulin resistance. As weight decreases and insulin sensitivity improves, fat tends to build up less in liver cells, and the inflammation that drives disease progression may ease.
In a clinical trial of adults with biopsy-confirmed MASH and moderate-to-advanced fibrosis (F2–F3), weekly semaglutide 2.4 mg was compared with placebo, both alongside standard care, over 72 weeks. At an interim analysis, semaglutide-treated patients showed significantly better liver histology outcomes than those on placebo, alongside an average weight loss of about 10.5%. Wegovy is not used on its own — providers pair it with dietary changes, physical activity, and regular monitoring, such as Liver Function Tests (LFTs), to support these outcomes.
LIVER BENEFITS
Excess weight and insulin resistance are major contributors to fat buildup in liver cells. By supporting significant, sustained weight loss, Wegovy addresses these underlying drivers and may help reduce the amount of fat stored in the liver.
In a MASH clinical trial, 62.9% of patients treated with semaglutide 2.4 mg achieved steatohepatitis resolution without worsening fibrosis at interim analysis, compared with 34.3% on placebo — a significant improvement in liver histology.
In the same trial, 36.8% of patients treated with semaglutide had at least a one-stage reduction in liver fibrosis without worsening steatohepatitis, compared with 22.4% on placebo, indicating a notable antifibrotic effect.
MASLD can progress to MASH, liver fibrosis, or cirrhosis over time. Improving the metabolic factors above — weight and insulin resistance — may help lower risk factors linked to disease progression, although individual outcomes vary.
Wegovy supports metabolic health by aiding significant, sustained weight loss, which may help people with MASLD or MASH. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Wegovy is supplied as a pre-filled injection pen. Check that the solution is clear and colorless, and that the pen has not expired, before each use. If it looks cloudy, discolored, or contains particles, do not use it — contact your pharmacist or healthcare provider instead.
Wegovy is delivered as a once-weekly injection under the skin (subcutaneously), into the abdomen, thigh, or upper arm. Rotate the injection site with each dose to help avoid skin irritation.
The typical dosage escalation is 0.25 mg once weekly for 4 weeks, then 0.5 mg, 1 mg, and 1.7 mg once weekly at 4-week intervals, before reaching the 2.4 mg once-weekly maintenance dose. Your healthcare provider determines the right dose and any adjustments based on how you respond.
Follow the specific instructions that come with your pen. Always use Wegovy exactly as your healthcare provider directs, injecting once weekly on the same day each week, with or without food.
Wegovy is intended for long-term weight management and is typically continued as long as it remains effective and well tolerated. Treatment should be used alongside ongoing lifestyle modifications and should not be discontinued without consulting your healthcare provider.
Store pens in the refrigerator before first use. After first use, follow the manufacturer's storage recommendations.
Attend regular follow-up visits to monitor weight loss, treatment response, and potential side effects. For people using Wegovy to support MASLD or MASH management, providers may also monitor liver health measures, such as Liver Function Tests (LFTs), alongside routine follow-up.
BENEFITS AND SAFETY
Wegovy (semaglutide) may support people with MASLD and MASH by producing significant, sustained weight loss — addressing the excess weight and insulin resistance that drive fat buildup and inflammation in the liver. By supporting weight loss, it may contribute to reduced liver fat and a lower risk of disease progression over time. The extent of these benefits varies from person to person, depending on their liver condition, overall metabolic health, treatment plan, and how their body responds to therapy. Wegovy is not a stand-alone liver treatment — it works best as part of a broader, personalised care plan that combines the medication with lifestyle changes, such as a liver-healthy diet and regular physical activity, along with ongoing monitoring like Liver Function Tests (LFTs) or imaging.
As with any medication, Wegovy may cause side effects, ranging from mild digestive symptoms to less common reactions. Your healthcare provider will assess whether Wegovy is a suitable option for you and will monitor your treatment response throughout therapy, adjusting the dose or overall care plan as needed to balance potential benefits against any risks.
BENEFITS
Wegovy has been shown to produce average weight loss of 15% or more in clinical trials, supporting long-term weight management rather than short-term results.
By supporting sustained weight loss, Wegovy improves blood pressure, cholesterol, and blood sugar levels, reducing the risk of obesity-related diseases.
By improving weight and insulin resistance, Wegovy addresses two of the main metabolic drivers behind fat buildup and inflammation in the liver. In a MASH trial, more patients on semaglutide achieved steatohepatitis resolution and fibrosis improvement than on placebo.
Wegovy is a once-weekly injection, offering a non-surgical medical approach to long-term weight management without daily dosing, making it a practical option for eligible patients.
These effects are often more noticeable when starting treatment or adjusting the dose and may improve over time. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support to ensure safe use.
SUPPORTING YOUR RESULTS
Lifestyle changes are an important part of a comprehensive treatment plan alongside Wegovy. Adjustments in nutrition, physical activity, weight management, and sleep may all play a role in supporting your results.
These habits can support how your body responds to treatment and may help improve outcomes over time.
Areas that may support treatment:
COMMON QUESTIONS
Wegovy is a GLP-1 receptor agonist approved for chronic weight management in adults and adolescents with obesity, or in adults who are overweight with a weight-related condition. Since August 2025, it is also approved for adults with MASH and liver fibrosis. It works by regulating appetite and slowing stomach emptying, which supports significant, sustained weight loss.
Ozempic and Wegovy both contain semaglutide and belong to the same GLP-1 receptor agonist class. Wegovy is given at a higher dose (up to 2.4 mg weekly) and is approved for chronic weight management and MASH with fibrosis, while Ozempic is approved for type 2 diabetes and, in some cases, weight management.
Wegovy is a once-weekly subcutaneous injection using a pre-filled pen, given in the abdomen, thigh, or upper arm. Treatment starts at 0.25 mg weekly and increases gradually over about 16 weeks to the 2.4 mg maintenance dose.
The most common side effects are digestive, including nausea, vomiting, diarrhea, or constipation. These often improve over time. Stomach pain, bloating, headache, and fatigue have also been reported. Rarely, injection site reactions occur.
In a clinical trial of adults with biopsy-confirmed MASH and moderate-to-advanced fibrosis, semaglutide led to steatohepatitis resolution in 62.9% of patients compared with 34.3% on placebo, and a fibrosis improvement in 36.8% compared with 22.4% on placebo, at interim analysis. This led the FDA to expand Wegovy's approval to MASH with fibrosis in August 2025.
Wegovy is generally used as a long-term, ongoing therapy for weight management rather than a short-term course. Continue treatment as prescribed, and do not stop taking it without first talking to your healthcare provider.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
